IFF Announces Further Evolution of its Board of Directors
27.2.2023 14:55:00 EET | Business Wire | Press release
IFF (NYSE: IFF) today announced the next phase of the evolution of its Board of Directors, to support the ongoing execution of the company’s strategic transformation and long-term financial vision.
Kevin O’Byrne, Chief Financial Officer and director of J Sainsbury Plc, has been appointed to join the IFF Board, effective March 10, 2023. O’Byrne is an established financial executive with decades of experience driving sustainable growth and overseeing transformation strategies for international consumer retail businesses. He brings to IFF a deep understanding of the consumer landscape and evolving expectations of CPG customers, which will be valuable to IFF as it continues to execute on its customer-centric and growth-focused strategy. O’Byrne will serve on the Board’s Audit, Innovation, and Transaction Committees.
IFF also announced that Edward (Ed) Breen and Matthias Heinzel, both of whom have served as directors and members of the Board’s Innovation Committee since 2021, have notified IFF of their respective decisions to retire from the Board. Breen and Heinzel will not stand for reelection at IFF’s 2023 Annual Meeting of Shareholders. In addition, Stephen Williamson, director since 2017 and a member of the Board’s Audit Committee, has notified IFF of his decision to retire from the Board effective March 10, 2023.
“On behalf of the entire Board, I would like to thank Ed, Stephen and Matthias for their many contributions to IFF,” said Dale Morrison, Chair of the IFF Board. “As directors, each has helped oversee the development of IFF’s refreshed growth strategy as we’ve become an even stronger partner for customers across the global value chain for consumer goods and commercial products. It has been an honor to work alongside these three leaders and I wish them all the best in their next chapters.”
“It has been a privilege to serve on the IFF Board as the company has established itself as the industry’s premier partner through the transformative combination of DuPont’s Nutrition and Biosciences business,” said Ed Breen, Director of the IFF Board. “Both the IFF Board and leadership team have taken strong action to position the company for long-term profitable growth and significant value creation, and I look forward to seeing all that IFF will accomplish in the future.”
“As we continue to evolve our Board of Directors, I am thrilled to welcome Kevin as an incoming director,” said Roger Ferguson, Incoming Chair of the IFF Board. “Kevin brings more than 30 years of retail and consumer goods experience to the IFF Board and a proven track record overseeing numerous multinational finance initiatives and successful business integrations. I am confident that his expertise and international perspective will be critical as we capture new growth opportunities, execute on our productivity initiatives and optimize our portfolio.”
O’Byrne is responsible for the finance, strategy, property, procurement and investor relations functions at J Sainsbury Plc, the second largest retailer in the United Kingdom. He will be retiring from Sainsbury's on March 4, 2023. Prior to joining J Sainsbury Plc, he served as Chief Executive Officer of Poundland Group Plc and held various leadership positions at Kingfisher Plc, including Divisional Director UK, China and Turkey, as well as Chief Executive Officer of B&Q UK & Ireland and Group Finance Director.
O’Byrne sits on the Board of Centrica Plc, the leading energy supply and in-home servicing provider in the UK and Ireland. He has chaired the Audit and Risk Committee since May 2019 and is the Senior Independent Director (SID). O’Byrne sat on the board of Land Securities Group Plc, the UK’s largest listed real estate group, for nine years where he chaired the Audit Committee and was SID.
“I am thrilled to join the IFF Board during such an exciting time for the company,” said Kevin O’Byrne, Incoming IFF Director. “IFF continues to lead the industry in delivering innovative solutions that meet the needs of today’s customers, and the company has a clear opportunity to realize its full potential. I look forward to partnering with Roger and the rest of the Board to help IFF become an even stronger industry leader, while driving sustainable, profitable growth.”
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
© 2023 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230226005174/en/
Contact information
Media Relations:
Paula Heinkel
332.877.5339
Media.request@iff.com
Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines’ BEQALZI ™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 20:27:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, and convenience over others in the class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513542161/en/ BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, N.J. Michael Wang, M.D., Global Principal Investigator
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this vision is colliding with skyrocketing cloud costs and trapped data. For many, layering agents onto a fragmented landscape only magnifies govern
Boomi and Couchbase Partner to Power Enterprise AI Agents with Trusted Recollection, Connectivity, and Governance13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, and Couchbase, Inc., the operational data platform for AI, today announced a partnership through which the two companies are collaborating closely to accelerate AI pilots to production. The companies will co-engineer solutions that give customers a production-ready foundation for agentic AI, combining Boomi's connectivity, runtime, and governance for AI agents with Couchbase's scalable recollection and vector capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513350337/en/ Enterprises deploying AI agents today face a common challenge: while agents perform well in pilots, they struggle to scale due to inconsistent access to trusted context, recollection, and real-time business data. Lack of governance, auditability, and operational control drives up compute costs while diminishing productivity and revenue. “2026 is the year organizations move from AI experimentation to a
Boomi and Red Hat Collaborate on Production-Ready Agentic AI13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, and Red Hat, the world’s leading provider of open source solutions, today announced a strategic collaboration to deliver a single, integrated stack for deploying agentic AI at scale. For many organizations, building production AI today means assembling numerous disconnected vendor choices spanning agent builders, orchestration tools, governance platforms, model providers, integration middleware, and security infrastructure, which can lead to data leaks and unpredictable costs. Boomi and Red Hat are working together to simplify AI innovation for customers by bringing together Boomi’s Agentstudio with the enterprise-grade power of Red Hat AI. This makes it easier for organizations to build agents that solve real business problems while supporting corporate standards for sovereignty, infrastructure flexibility, and performance reliability. Together, Boomi and Red Hat are collaborating to deliver an integrated solution designed to simplify how org
Lenovo Named a Leader and Star Performer in Mid-Market Digital Workplace Solutions Assessment by Everest Group13.5.2026 16:00:00 EEST | Press release
Lenovo’s ability to help mid‑market organizations reduce IT support costs, accelerate time-to-value, and improve workforce productivity at scale has earned recognition as a Leader and Star Performer in Everest Group’s 2026 Digital Workplace Services PEAK Matrix® Assessment for Mid‑Market Enterprises. Lenovo’s Digital Workplace Solutions (DWS) enable customers to improve speed, cut costs, and elevate employee experiences, helping new employees reach productivity up to 50% faster, increasing employee satisfaction by 30%, lowering end-user support costs by up to 30%, and proactively resolving up to 40% of issues to minimize downtime and business disruption1. Lenovo delivers these results by uniquely integrating device, services, and intelligence into a single, scalable delivery model built for the mid‑market. Through lifecycle services delivered at global scale, AI‑powered automation and insights from Lenovo xIQ, and consumption‑based flexibility through TruScale DaaS, customers gain cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
